The claim runs outside your Aetna Part D plan: the pharmacy routes it to a CMS central processor with an obesity diagnosis code, and the prior-authorization request reaches your prescriber within 2472 hours
Because CJC-1295 can influence growth hormone and IGF-1 signaling, a provider should review your labs, symptoms, medications, sleep, metabolic health, and medical history before treatment is considered
Bottom line Navigating BCBS coverage for Wegovy can be tricky, but understanding your plans specific policies and coverage options is essential
After a median follow-up of 7.9 years, the primary endpoint, 5-year disease-free survival, was 80.3% in the exercise group and 73.9% in the control group (difference, 6.4 percentage points